EGFR and non-small cell lung carcinoma: Since 2009, several first-line Phase III trials have revealed the impressive clinical activity of first- (gefitinib and erlotinib) and second- (afatinib) generation EGFR-TKIs over platinum-doublet chemotherapy, for advanced NSCLC EGFR-mutated patients (75–82).